Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Cambridge and GSK announce a new five-year collaboration to improve outcomes for patients with hard-to-treat kidney and respiratory diseases
Oct 21, 2024•over 1 year ago
Contract Type
partnership
LondonBiotechnologyHealth CareDescription
Cambridge and GSK have announced a new five-year collaboration, the Cambridge-GSK Translational Immunology Collaboration (CG-TIC), focused on understanding the onset, progression, and treatment response of kidney and respiratory diseases. GSK is investing more than £50 million in this collaboration, strengthening Cambridge’s leading position in life sciences.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months